FLAMINGO-01 Interim Data Signals Scale-Up Pressure for GLSI-100

Greenwich LifeSciences is bringing preliminary Phase III efficacy and immunogenicity data for GLSI-100 to the 2026 ASCO Annual Meeting, and the figures will draw scrutiny well beyond the clinical community. A preliminary analysis from the fully enrolled 250-patient non-HLA-A*02 open-label arm of FLAMINGO-01 shows an approximately 70-80% reduction in breast cancer recurrence rate following completion of the Primary Immunization Series, a trajectory that mirrors Phase IIb results in HLA-A*02 patients where recurrences were reduced up to 80%. For manufacturing and regulatory teams at clinical-stage biotechs, data at this scale begins to define the process validation envelope long before a BLA filing is contemplated.

The dosing architecture of GLSI-100 carries direct implications for commercial-scale planning. The Primary Immunization Series consists of six injections administered over six months, followed by five booster injections given every six months. With more than 1,300 patients screened and a current screen rate of approximately 800 patients per year, demand forecasting and batch release cadence will require early alignment between clinical operations and CMC functions. Immunotherapy products administered on extended schedules introduce sterility assurance and cold-chain continuity considerations that must be addressed under 21 CFR Part 211 and ICH Q10 quality system frameworks before pivotal supply commitments are made.

Immunogenicity data presented at AACR 2026 adds another layer of process relevance. Delayed-type hypersensitivity reaction frequency increased approximately fourfold in the non-HLA-A*02 open-label population, rising from 5.2% at baseline to 20.4% at month four or six, a statistically significant shift (McNemar, p less than 0.001). Each HLA-A type exhibited increased immune reactivity post-treatment, with frequency rising between 100% and 700% above baseline. Notably, baseline DTH reactions prior to any GLSI-100 administration suggest GP2 may function as a natural antigen, a finding also observed in the Phase IIb trial, with implications for patient stratification protocols and lot release immunogenicity specifications.

Greenwich LifeSciences stated the ASCO abstract was co-authored with the full FLAMINGO-01 Steering Committee and will be the second such collaborative publication. The abstract and corresponding poster will be publicly available on June 1, 2026. The company also indicated plans to attend ESMO Breast and BIO partnering events in the coming months. For QA directors and regulatory affairs leads tracking peptide-based immunotherapy pipelines, FLAMINGO-01 represents an early reference point for how extended-schedule cancer vaccines may need to be characterized, released, and monitored at commercial scale.